Infliximab en el tratamiento de la enfermedad de Crohn: Estudio preliminar
Background: Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn's disease. Infliximab, a monoclonal antibody against tumor necrosis factor, is useful in the treatment of Crohn's disease, specially when the disease is active and associated to fistula formation....
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Lenguaje: | Spanish / Castilian |
| Publicado: |
Sociedad Médica de Santiago
2006
|
| Materias: | |
| Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006000300008 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:scielo:S0034-98872006000300008 |
|---|---|
| record_format |
dspace |
| spelling |
oai:scielo:S0034-988720060003000082006-05-02Infliximab en el tratamiento de la enfermedad de Crohn: Estudio preliminarGellona V,JoséZarraonandia A,AntónZúñiga D,AlvaroPalma C,RenatoContreras P,JaimeSilva Ch,JaimeGonzález D,RóbinsonQuintana V,Carlos Antibodies, monoclonal Crohn's disease Infliximab Tumor necrosis factor-alpha Background: Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn's disease. Infliximab, a monoclonal antibody against tumor necrosis factor, is useful in the treatment of Crohn's disease, specially when the disease is active and associated to fistula formation. Aim: To assess the effectiveness of Infliximab in patients with Crohn's disease. Material and methods: Twelve patients with Crohn's disease (aged 16 to 63 years, 10 women) refractory to treatment with steroid, 5-aminosalicylic acid, antimicrobials and immunomodulatory drugs, were studied. A single intravenous 5 mg/kg dose Infliximab was administered. The Crohn's disease activity index (CDAI) was measured before and one week after the administration of the drug. Results: CDAI before and after Infliximab administration was 357±62 and 138±122 score points, respectively (p <0.005). According to this score, five patients had a severe and seven a moderate disease flare. The disease remitted in 7 (58%) and a clinical response was observed in 75%. Conclusions: A single dose of Infliximab was effective to induce remission of the disease in 75% of this selected group of patients with Crohn's diseaseinfo:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.134 n.3 20062006-03-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006000300008es10.4067/S0034-98872006000300008 |
| institution |
Scielo Chile |
| collection |
Scielo Chile |
| language |
Spanish / Castilian |
| topic |
Antibodies, monoclonal Crohn's disease Infliximab Tumor necrosis factor-alpha |
| spellingShingle |
Antibodies, monoclonal Crohn's disease Infliximab Tumor necrosis factor-alpha Gellona V,José Zarraonandia A,Antón Zúñiga D,Alvaro Palma C,Renato Contreras P,Jaime Silva Ch,Jaime González D,Róbinson Quintana V,Carlos Infliximab en el tratamiento de la enfermedad de Crohn: Estudio preliminar |
| description |
Background: Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn's disease. Infliximab, a monoclonal antibody against tumor necrosis factor, is useful in the treatment of Crohn's disease, specially when the disease is active and associated to fistula formation. Aim: To assess the effectiveness of Infliximab in patients with Crohn's disease. Material and methods: Twelve patients with Crohn's disease (aged 16 to 63 years, 10 women) refractory to treatment with steroid, 5-aminosalicylic acid, antimicrobials and immunomodulatory drugs, were studied. A single intravenous 5 mg/kg dose Infliximab was administered. The Crohn's disease activity index (CDAI) was measured before and one week after the administration of the drug. Results: CDAI before and after Infliximab administration was 357±62 and 138±122 score points, respectively (p <0.005). According to this score, five patients had a severe and seven a moderate disease flare. The disease remitted in 7 (58%) and a clinical response was observed in 75%. Conclusions: A single dose of Infliximab was effective to induce remission of the disease in 75% of this selected group of patients with Crohn's disease |
| author |
Gellona V,José Zarraonandia A,Antón Zúñiga D,Alvaro Palma C,Renato Contreras P,Jaime Silva Ch,Jaime González D,Róbinson Quintana V,Carlos |
| author_facet |
Gellona V,José Zarraonandia A,Antón Zúñiga D,Alvaro Palma C,Renato Contreras P,Jaime Silva Ch,Jaime González D,Róbinson Quintana V,Carlos |
| author_sort |
Gellona V,José |
| title |
Infliximab en el tratamiento de la enfermedad de Crohn: Estudio preliminar |
| title_short |
Infliximab en el tratamiento de la enfermedad de Crohn: Estudio preliminar |
| title_full |
Infliximab en el tratamiento de la enfermedad de Crohn: Estudio preliminar |
| title_fullStr |
Infliximab en el tratamiento de la enfermedad de Crohn: Estudio preliminar |
| title_full_unstemmed |
Infliximab en el tratamiento de la enfermedad de Crohn: Estudio preliminar |
| title_sort |
infliximab en el tratamiento de la enfermedad de crohn: estudio preliminar |
| publisher |
Sociedad Médica de Santiago |
| publishDate |
2006 |
| url |
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006000300008 |
| work_keys_str_mv |
AT gellonavjose infliximabeneltratamientodelaenfermedaddecrohnestudiopreliminar AT zarraonandiaaanton infliximabeneltratamientodelaenfermedaddecrohnestudiopreliminar AT zunigadalvaro infliximabeneltratamientodelaenfermedaddecrohnestudiopreliminar AT palmacrenato infliximabeneltratamientodelaenfermedaddecrohnestudiopreliminar AT contreraspjaime infliximabeneltratamientodelaenfermedaddecrohnestudiopreliminar AT silvachjaime infliximabeneltratamientodelaenfermedaddecrohnestudiopreliminar AT gonzalezdrobinson infliximabeneltratamientodelaenfermedaddecrohnestudiopreliminar AT quintanavcarlos infliximabeneltratamientodelaenfermedaddecrohnestudiopreliminar |
| _version_ |
1718436250551058432 |